The North American oncolytic virus therapy market is estimated to grow at a CAGR of more than 16% during the forecast period. The market growth is attributed to the established research environment for various biotechnologies, the presence of major healthcare providers and growing healthcare investment in the US and Canada. Moreover, a growing number of cancer patients is augmenting the demand for oncolytic virus therapy. T-Vec (talimogene laherparepvec), is a recently approved oncolytic virus drug in the US and Europe. It is the second-generation oncolytic drug armed with GM-CSF to cure cancer.
Please read the originial post here: https://www.omrglobal.com/industry-reports/north-american-oncolytic-virus-therapy-market